Intellia Therapeutics, Inc. - 10-Q Filing

Intellia Therapeutics reports Q3 2026 financial results including new OrbiMed credit facility and ongoing R&D activities.

SEC EDGAR ·

Tickers: $NTLA

Read the full article at SEC EDGAR

More Regulatory news